# Asymchem

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/asymchem

- Industry: Pharmaceuticals
- Headquarters: Tianjin, China
- Website: www.asymchem.com
- Total disclosed funding: $5.4M
- Latest round: Series B (Dec 7, 2012)
- Investors on record: 4

## About

Founded in 1998 and based in Tianjin, China, Asymchem Inc. operates as a pharmaceutical company that focuses on the development and production of new drugs and APIs. The company has 8 R&D and production bases, as well as more than 20 R&D, production, and sales subsidiaries and offices located in Tianjin, Jilin, Shanghai, and other places. It cooperated with global pharmaceutical companies such as Pfizer, Merck, AbbVie, etc. Hao Hong, the chairman and CEO of the company, graduated from the Chinese Academy of Medical Sciences and is also a visiting professor at Sichuan University. In December 2021, the company was listed on the Hong Kong Stock Exchange. In February 2020, Asymchem Laboratories raised a PIPE funding for CNY 2.31 billion.

The company is mainly engaged in the research and development of new drugs and drug APIs. It combines molecular biology technology, fermentation technology, and process development technology to provide users with carbapenem drugs, cGMP APIs and other products. The products can be used to treat major diseases such as antiviral, anticancer, cardiovascular and cerebrovascular diseases, and diabetes.

The company generates revenue by providing new drugs and APIs.

## Funding rounds

- Series B, Dec 7, 2012 — CoStone Capital
- Series A, Jun 20, 2011, $5.4M — Tianjin Venture Capital, CoStone Capital, Wings Capital, Huafang Group

## Investors

- Tianjin Venture Capital (https://capitalatlas.ai/funds/tianjin-venture-capital) — Series A
- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Series A, Series B
- Wings Capital (https://capitalatlas.ai/funds/wings-capital) — Series A
- Huafang Group — Series A